

RFI Response: GLP-1 Solutions

RFI Number: 270-20240419GLP

Submitted to: North Carolina State Health Plan for Teachers and State Employees

Submitted by: Compounding Doctors

Date: [Current Date]

Executive Summary

Compounding Doctors acknowledges the North Carolina State Health Plan's critical need to balance providing essential weight loss medications with maintaining financial sustainability. We understand the complexity of this challenge and appreciate the opportunity to offer our perspective on potential solutions.

While we recognize that the RFI requests detailed information across multiple areas, we believe that addressing the core issue—providing safe, effective, and affordable GLP-1 agonists—is paramount. Therefore, our response focuses on this central concern, outlining a viable approach that we believe will merit serious consideration for any future RFP.

Proposed Solution: Core Offering

Our primary proposal centers on providing two key medications at significantly reduced prices. As of this writing, the prices we can put forth are as follows:

1. Semaglutide: [REDACTED]
2. Tirzepatide: [REDACTED]

These prices represent a substantial reduction from the current market rates, potentially allowing the Plan to extend coverage to more members who need these medications while dramatically reducing overall expenditure.

Key Benefits

1. **Cost Effectiveness:** Our pricing model could result in savings of [REDACTED] compared to current expenditures, addressing the Plan's primary concern of financial sustainability.
2. **Quality Assurance:** As licensed compounding professionals, we adhere to stringent quality control measures, ensuring the safety and efficacy of our products.
3. **Customization Potential:** [REDACTED]
[REDACTED]

4. Scalability: We are already in the process of increasing our production capacity to meet the needs of other high volume clients, which would also be able to meet the Plan's large membership base, ensuring consistent supply and timely delivery.

Implementation Considerations

While detailed implementation plans would be more appropriate for an RFP stage, we want to assure the Plan that we have been developing the infrastructure and expertise to rapidly scale our operations to meet your needs. We are prepared to work closely with the Plan to develop appropriate eligibility criteria, monitoring protocols, and distribution systems that align with your objectives.

Conclusion

We believe our approach offers a viable path to addressing the Plan's most pressing concern: providing essential weight loss medications at a sustainable cost. By focusing on high-quality, affordable compounded versions of semaglutide and tirzepatide, we can help the Plan significantly reduce its expenditure while maintaining—and potentially expanding—access to these crucial treatments.

We appreciate that this response does not address all the detailed points outlined in the RFI. However, we believe that by concentrating on the core issue of affordable medication supply, we present a compelling case for consideration in any future RFP process. We are, of course, prepared to provide more detailed information on any aspect of our proposal should the Plan require it.

We look forward to the possibility of partnering with the North Carolina State Health Plan to create a sustainable model for providing these life-changing medications to your members.

Contact Information:

Compounding Doctors
720 N Tustin Ave #202
Santa Ana, CA 92705

Mark Anthony Bates
Equity Holder
Compounding Doctors

Email: MarkAnthonyBates@gmail.com
Mobile: 619-847-8743